A Phase 2 interventional study of SB1518 in Hodgkin Lymphoma, Mantle Cell Lymphoma and Indolent Lymphoma, sponsored by S*BIO. Completed at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-04-20.
Sponsored by S*BIO · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 970 studies in Hodgkin Disease with a site in United States — 75 open to participants now, 142 under way, 6 of them phase 3. Hodgkin Disease · United States.
Among the 970 studies in Hodgkin Disease with a site in United States, this one is the 482nd largest by enrollment of the 818 interventional ones that give a count, is one of 48 that started in 2010, is one of 346 in phase 2, and was the 563rd registered.
1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.
Browse Hodgkin Disease studies →75 of the 970 studies in Hodgkin Disease with a site in United States are open now. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18–75 · Healthy volunteers
St. Jude Children's Research Hospital · Sites in United States
M.D. Anderson Cancer Center · Sites in United States
Ages 2–21
Michael Spinner, MD · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
970 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 389 · Phase 2 460 · Phase 3 57 · Phase 4 1
First in 1988; this study’s year is marked. 48 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 40 across 1,095 interventional studies indexed under Hodgkin Disease.
Median enrollment 35 across the 818 interventional studies, 111 across the 80 observational. Of the 779 that completed or were terminated, 326 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
137 of 970 have an industry lead sponsor. The 10 most frequent:
S*BIO is the lead sponsor of 6 studies on the registry; none are open to participants now.
S*BIO has 2 studies filed under Hodgkin Disease — fewer than ten, so there is no comparison to draw.
49 of the studies in Hodgkin Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01483664Memorial Sloan Kettering Cancer CenterCommunication Skills Intervention to Promote Transition Into Survivorship | 2026-11 |
| NCT03681561Veronika BachanovaNivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma | 2026-11 |
| NCT06923397Dana-Farber Cancer InstituteInterrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial | 2026-11-28 |
| NCT05723055University of UtahEvaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma | 2026-12 |
| NCT06150664Compass TherapeuticsA Phase 1 of CTX-8371 in Patients With Advanced Malignancies | 2026-12 |
Add all 49 to your calendar (.ics) → With an account.
Among the 970 studies in Hodgkin Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2 study to assess the efficacy of SB1518 in the treatment of patients with advanced lymphoid malignancies including Hodgkin Lymphoma, Mantle Cell Lymphoma and Indolent Lymphoma (follicular lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma and small lymphocytic lymphoma).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SB1518
SB1518 taken orally daily for 28 consecutive days in a 28 day cycle.
Assess overall tumor response of SB1518 by CT/FDG-PET scan and bone marrow biopsy as applicable as a measure of efficacy
Outcome Measure - To assess the efficacy of SB1518 in the treatment of patients with advanced lymphoid malignancies including Hodgkin Lymphoma, Mantle Cell Lymphoma and Indolent Lymphoma (follicular lymphoma, lymphophasmacytic lymphoma, marginal zone lymphoma and small lymphocytic lymphoma).
Time frame: Every even numbered cycle from baseline to 30 days after the last dose of study medication
Assess durability of response
To assess the durability of response following SB1518 treatment in patients with advanced lymphoid malignancies.
Time frame: Every even numbered cycle from baseline to 30 days after the last dose of study medication
Assess number of patients with adverse events as a measure of safety and tolerability
To assess the safety and tolerability of SB1518 administered orally once daily in patients with advanced lymphoid malignancies.
Time frame: Every even numbered cycle from baseline to 30 days after the last dose of study medication
The record gives a start of Dec 2010, a primary completion of Feb 2012 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pacritinib
S*BIO